tiprankstipranks
Trending News
More News >
Gland Pharma Ltd. (IN:GLAND)
:GLAND
India Market

Gland Pharma Ltd. (GLAND) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

GLAND Analyst Ratings

Moderate Sell
1Ratings
Moderate Sell
0 Buy
0 Hold
1 Sell
Based on 1 analysts giving stock ratings to
Gland
Pharma Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GLAND Stock 12 Month Forecast

Average Price Target

₹1,435.00
▼(-4.08%Downside)
Based on 1 Wall Street analysts offering 12 month price targets for Gland Pharma Ltd. in the last 3 months. The average price target is ₹1,435.00 with a high forecast of ₹1,435.00 and a low forecast of ₹1,435.00. The average price target represents a -4.08% change from the last price of ₹1,496.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1434":"₹1,434","2101":"₹2,101","1600.75":"₹1,600.8","1767.5":"₹1,767.5","1934.25":"₹1,934.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.44K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.44K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.44K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1434,1600.75,1767.5,1934.25,2101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Jan<br/>2025","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1555.05,1545.8153846153846,1536.5807692307692,1527.3461538461538,1518.1115384615384,1508.876923076923,1499.6423076923077,1490.4076923076923,1481.173076923077,1471.9384615384615,1462.7038461538461,1453.4692307692308,1444.2346153846154,{"y":1435,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1555.05,1545.8153846153846,1536.5807692307692,1527.3461538461538,1518.1115384615384,1508.876923076923,1499.6423076923077,1490.4076923076923,1481.173076923077,1471.9384615384615,1462.7038461538461,1453.4692307692308,1444.2346153846154,{"y":1435,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1555.05,1545.8153846153846,1536.5807692307692,1527.3461538461538,1518.1115384615384,1508.876923076923,1499.6423076923077,1490.4076923076923,1481.173076923077,1471.9384615384615,1462.7038461538461,1453.4692307692308,1444.2346153846154,{"y":1435,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1693.98,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1820.38,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1801.23,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2100.49,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1833.25,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1799.9,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1650.85,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1779.4,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1779.4,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1809.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1526.4,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1552.4,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1555.05,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target₹1,435Average Price Target₹1,435Lowest Price Target₹1,435
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on IN:GLAND
Shyam SrinivasanGoldman Sachs
Goldman Sachs
₹1,450₹1,435
Sell
-4.08%
Downside
Reiterated
04/18/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,435 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,435.00 (from INR1,450.00) while maintaining a Sell rating.
Nomura
₹1,790₹1,570
Hold
4.94%
Upside
Reiterated
02/07/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,570 at Nomura/InstinetNomura/Instinet analyst Saion Mukherjee lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,570.00 (from INR1,790.00) while maintaining a Neutral rating.
Jefferies Analyst forecast on IN:GLAND
Alok DalalJefferies
Jefferies
₹1,630₹1,350
Sell
-9.76%
Downside
Reiterated
02/04/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,350 at JefferiesJefferies analyst Alok Dalal lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,350.00 (from INR1,630.00) while maintaining a Underperform rating.
Investec
₹2,055₹1,750
Buy
16.97%
Upside
Reiterated
02/04/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,750 at InvestecInvestec analyst Anshuman Gupta lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,750.00 (from INR2,055.00) while maintaining a Buy rating.
Bank of America Securities Analyst forecast on IN:GLAND
Neha ManpuriaBank of America Securities
Bank of America Securities
₹2,080₹2,020
Buy
35.02%
Upside
Reiterated
02/04/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR2,020 at BofA SecuritiesBofA Securities analyst Neha Manpuria lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR2,020.00 (from INR2,080.00) while maintaining a Buy rating.
Kotak Mahindra Analyst forecast on IN:GLAND
Alankar GarudeKotak Mahindra
Kotak Mahindra
₹1,625
Sell
8.62%
Upside
Reiterated
12/27/24
Kotak Reiterates Reduce (3) Rating on Gland Pharma Ltd (GLAND:IN)Kotak analyst Alankar Garude reiterated a Reduce (3) rating and INR1,625.00 price target on Gland Pharma Ltd (GLAND:IN).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on IN:GLAND
Shyam SrinivasanGoldman Sachs
Goldman Sachs
₹1,450₹1,435
Sell
-4.08%
Downside
Reiterated
04/18/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,435 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,435.00 (from INR1,450.00) while maintaining a Sell rating.
Nomura
₹1,790₹1,570
Hold
4.94%
Upside
Reiterated
02/07/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,570 at Nomura/InstinetNomura/Instinet analyst Saion Mukherjee lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,570.00 (from INR1,790.00) while maintaining a Neutral rating.
Jefferies Analyst forecast on IN:GLAND
Alok DalalJefferies
Jefferies
₹1,630₹1,350
Sell
-9.76%
Downside
Reiterated
02/04/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,350 at JefferiesJefferies analyst Alok Dalal lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,350.00 (from INR1,630.00) while maintaining a Underperform rating.
Investec
₹2,055₹1,750
Buy
16.97%
Upside
Reiterated
02/04/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR1,750 at InvestecInvestec analyst Anshuman Gupta lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR1,750.00 (from INR2,055.00) while maintaining a Buy rating.
Bank of America Securities Analyst forecast on IN:GLAND
Neha ManpuriaBank of America Securities
Bank of America Securities
₹2,080₹2,020
Buy
35.02%
Upside
Reiterated
02/04/25
Gland Pharma Ltd (GLAND:IN) PT Lowered to INR2,020 at BofA SecuritiesBofA Securities analyst Neha Manpuria lowered the price target on Gland Pharma Ltd (GLAND:IN) to INR2,020.00 (from INR2,080.00) while maintaining a Buy rating.
Kotak Mahindra Analyst forecast on IN:GLAND
Alankar GarudeKotak Mahindra
Kotak Mahindra
₹1,625
Sell
8.62%
Upside
Reiterated
12/27/24
Kotak Reiterates Reduce (3) Rating on Gland Pharma Ltd (GLAND:IN)Kotak analyst Alankar Garude reiterated a Reduce (3) rating and INR1,625.00 price target on Gland Pharma Ltd (GLAND:IN).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gland Pharma Ltd.

1 Month
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
+6.40%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +6.40% per trade.
3 Months
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+12.85%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +12.85% per trade.
1 Year
Alok DalalJefferies
Success Rate
0/2 ratings generated profit
0%
Average Return
-16.60%
reiterated a sell rating 5 months ago
Copying Alok Dalal's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -16.60% per trade.
2 Years
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-16.05%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -16.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GLAND Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
0
0
0
Buy
0
0
2
2
2
Hold
0
1
2
2
1
Sell
1
3
5
5
4
Strong Sell
0
0
0
0
0
total
1
4
9
9
7
In the current month, GLAND has received 2 Buy Ratings, 1 Hold Ratings, and 4 Sell Ratings. GLAND average Analyst price target in the past 3 months is 1,435.00.
Each month's total comprises the sum of three months' worth of ratings.

GLAND Financial Forecast

GLAND Earnings Forecast

Next quarter’s earnings estimate for GLAND is ₹13.38 with a range of ₹13.06 to ₹13.70. The previous quarter’s EPS was ₹11.30. GLAND beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year GLAND has Preformed in-line its overall industry.
Next quarter’s earnings estimate for GLAND is ₹13.38 with a range of ₹13.06 to ₹13.70. The previous quarter’s EPS was ₹11.30. GLAND beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year GLAND has Preformed in-line its overall industry.

GLAND Sales Forecast

Next quarter’s sales forecast for GLAND is ₹15.18B with a range of ₹14.91B to ₹15.66B. The previous quarter’s sales results were ₹14.25B. GLAND beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year GLAND has Preformed in-line its overall industry.
Next quarter’s sales forecast for GLAND is ₹15.18B with a range of ₹14.91B to ₹15.66B. The previous quarter’s sales results were ₹14.25B. GLAND beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year GLAND has Preformed in-line its overall industry.

GLAND Stock Forecast FAQ

What is IN:GLAND’s average 12-month price target, according to analysts?
Based on analyst ratings, Gland Pharma Ltd.’s 12-month average price target is 1,435.00.
    What is IN:GLAND’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for IN:GLAND, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Gland Pharma Ltd. a Buy, Sell or Hold?
        Gland Pharma Ltd. has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 0 hold ratings and 1 sell ratings.
          What is Gland Pharma Ltd.’s share price target?
          The average share price target for Gland Pharma Ltd. is 1,435.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is ₹1,435.00 ,and the lowest forecast is ₹1,435.00. The average share price target represents -4.08% Decrease from the current price of ₹1,496.05.
            What do analysts say about Gland Pharma Ltd.?
            Gland Pharma Ltd.’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 1 Wall Streets Analysts.
              How can I buy shares of Gland Pharma Ltd.?
              To buy shares of IN:GLAND, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis